Close
Achema middle east
swop processing & packaging

Alnylam concludes liver cancer drug Phase I trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

Pharma Supply Chain and Customs Clearance Solutions

The Critical Challenge of Pharmaceutical Customs Clearance The pharmaceutical industry...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

US based drug developer Alnylam Pharmaceuticals has concluded an open label, multi-center, dose escalation Phase I trial evaluating ALN-VSP as a treatment for advanced solid tumors with liver involvement.

ALN-VSP is a systemically delivered RNAi therapeutic which includes two siRNAs intended to target two genes critical for the growth and development of cancer cells: vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP), also known as eglin 5 (Eg5).

In the trial, the patients were treated at doses ranging from 0.1 to 1.5 mg/kg. Alnylam Clinical Research senior director Jared Gollob said the results of ALN-VSP Phase I trial demonstrated safety and tolerability of multiple doses of ALN-VSP in addition to evidence for anti-tumor activity and proof of RNAi mechanism from tissue biopsy samples.

 

Latest stories

Related stories

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

Pharma Supply Chain and Customs Clearance Solutions

The Critical Challenge of Pharmaceutical Customs Clearance The pharmaceutical industry...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »